Subscribe to Newsletter
Subspecialties Retina

Combining Laser and Anti-VEGF for the Treatment of DME

| Stela Vujosevic

Advances in understanding of the therapeutic mechanisms that underpin micropulse laser treatment suggest that protocols for treatment of diabetic macular edema should be integrated.

Business & Profession Professional Development

How to Improve Visual Acuity Testing

| Florian Kretz

The Salzburg Reading Desk is one promising approach to standardizing visual assessments for multifocal intraocular lenses.

Business & Profession Professional Development

Why Snellen Must Die

| Mark Blecher

For the sake of our patients and our profession, we need to improve upon the nineteenth-century pictograms that are currently used for visual assessment.

Business & Profession Cataract

A Vision Timebomb

| Mark Hillen

Although baby boomers may be in a state of denial regarding their own aging, ophthalmologists know differently. In particular, four diseases of the ageing eye comprise a demographic and economic timebomb.

Business & Profession Professional Development

Business in Brief

| Mark Hillen

Aflibercept gets approved by NICE, STAAR’s Visian ICL with CentraFLOW gets approved in Japan, and rises and falls in Allergan and Alcon’s revenues.

Business & Profession Professional Development

Big in Japan

| Mark Hillen

Acucela prices its initial public offering on the Tokyo Stock Exchange at $162M.

Subspecialties Glaucoma

All is Not Lost

| Mark Hillen

Vision training can restore some of the sight lost to glaucoma.

Subspecialties Basic & Translational Research

STAP! Not so fast

| Mark Hillen

The new method to produce stem cells has run into difficulties in the form of image irregularities and the failure of other labs to reproduce the findings.

Subspecialties Retina

Aspirin not Linked to AMD

| Mark Hillen

Previous studies linked aspirin use with age-related macular degeneration, but new data suggest otherwise: aspirin is innocent of all charges.

Subspecialties Retina

Statins Protect Elderly Against Macular Degeneration

| Mark Hillen

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: